Evotec AG (ETR:EVT) has been given a €16.00 ($19.05) price objective by stock analysts at Berenberg Bank in a research note issued to investors on Tuesday. The brokerage currently has a “neutral” rating on the stock.
Several other research firms also recently weighed in on EVT. Deutsche Bank AG set a €16.00 ($19.05) target price on shares of Evotec AG and gave the stock a “neutral” rating in a research report on Wednesday, August 30th. Oddo Securities set a €14.00 ($16.67) target price on shares of Evotec AG and gave the stock a “neutral” rating in a research report on Friday, August 11th.
Evotec AG (ETR EVT) opened at 18.625 on Tuesday. The company has a market cap of €2.73 billion and a P/E ratio of 75.101. The company’s 50-day moving average is €15.65 and its 200-day moving average is €12.51. Evotec AG has a 12 month low of €4.63 and a 12 month high of €19.34.
Evotec AG Company Profile
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.